Cover Letter for NCI Consent Form Template - Cancer Therapy ...
Cover Letter for NCI Consent Form Template - Cancer Therapy ...
Cover Letter for NCI Consent Form Template - Cancer Therapy ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
The dedicated ef<strong>for</strong>ts of the Working Group members who prepared this version of the <strong>Template</strong><br />
are greatly appreciated. Their names are also posted on the CTEP website. Additional helpful<br />
documents posted on the CTEP website, in the “In<strong>for</strong>med <strong>Consent</strong>” section found under the<br />
“Protocol Development” tab include:<br />
<strong>Consent</strong> <strong>for</strong>m example <strong>for</strong> a Phase 2 treatment trial, written using revised <strong>Template</strong><br />
<strong>Consent</strong> <strong>for</strong>m example <strong>for</strong> a Phase 3 treatment trial, written using revised <strong>Template</strong><br />
<strong>Letter</strong> of rationale addressed to IRB Chairs and Members<br />
Instructions <strong>for</strong> building “Tables of Possible Side Effects”<br />
<strong>NCI</strong> Scientific Term CTCAE – IC Term Spreadsheet 12-12-12<br />
Repository of “Tables” <strong>for</strong> commonly-used commercials drugs<br />
Repository of “Tables” <strong>for</strong> commonly-used regimens (to be added within the year)<br />
CTEP will begin using the February 15, 2013 version of the <strong>Template</strong> <strong>for</strong> review of your consent<br />
<strong>for</strong>m documents as of May 15, 2013. Please utilize the February 15, 2013 version of the<br />
<strong>Template</strong> to guide preparation of consent <strong>for</strong>m documents on all new protocol submissions to<br />
<strong>NCI</strong> as soon as possible.<br />
Your support of more concise consent <strong>for</strong>ms is appreciated and assists the <strong>NCI</strong> to better in<strong>for</strong>m<br />
prospective study participants.<br />
Best regards,<br />
Jeffrey Abrams, M.D.<br />
Associate Director, <strong>Cancer</strong> <strong>Therapy</strong> Evaluation Program<br />
Acting Director <strong>for</strong> Clinical Research<br />
Division of <strong>Cancer</strong> Treatment and Diagnosis<br />
National <strong>Cancer</strong> Institute<br />
Page 2 of 2